Sign in
Active, not recruitingNo phase

Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial

Key facts

Who runs it
Edwards Lifesciences
Where
Albany, Ann Arbor, Atlanta, Boston, Buffalo, Carmel, Charlottesville, Chicago, Cincinnati, Cleveland, Detroit, Gainesville, Houston, Iowa City, Kansas City, Kingsport, La Jolla, Los Angeles, Loveland, Memphis, Miami Beach, Milwaukee, Mineola, Morristown, Naples, Nashville, New Brunswick, New York, Norfolk, Oklahoma City, Orange, Orlando, Philadelphia, Phoenix, Pittsburgh, Plano, Portland, Rochester, Sacramento, Salt Lake City, San Francisco, Seattle, St Louis, Stanford, The Bronx, Thousand Oaks, Tucson, Tulsa, Washington D.C., Wormleysburg, Wynnewood, and York, United StatesSee the 63 sitesAlso in 3 other countries, 18 sites
Trial code
Status
Active, not recruiting
People taking part
1,247 people, planned
Started
30 Nov 2018
Expected to end
30 Jun 2031
Type of study
Interventional, 5 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Edwards PASCAL System
  • Abbott Mitraclip System
Record updated
8 July 2026

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 27 criteriaShow less

Who can take part

  • Eighteen (18) years of age or older
  • Patient is able and willing to give informed consent and follow protocol procedures, and comply with follow-up visit requirements
  • Patient is determined to be at prohibitive risk for mitral valve surgery by the heart team (CLASP IID cohort only)
  • Patient is on stable heart failure medications/Guideline Directed Medical Therapy (CLASP IIF cohort only)
  • Patient is determined to be a candidate for transcatheter mitral valve repair by the heart team for both PASCAL and MitraClip
  • Mitral regurgitation (3+ to 4+) by echo
  • Suitable valve and regurgitant jet morphology
  • Elevated corrected BNP > 400 pg/ml or corrected NT-pro BNP of > 900 pg/ml or heart failure hospitalization within the past 12 months (CLASP IIF cohort only)
  • LVEF ≥ 20% (and ≤ 50%; CLASP IIF cohort only)

Who cannot take part

  • Any prior mitral valve surgery or transcatheter mitral valve procedure (excluding chordal replacement or surgical annuloplasty repair)
  • Pregnant or planning pregnancy within next 12 months. Note: Female patients of childbearing potential need to have a negative pregnancy test performed within 14 days prior to intervention and be adherent to an accepted method of contraception
  • Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
  • Patient is currently participating in another investigational biologic, drug or device clinical study where the primary study endpoint was not reached at time of enrollment
  • Patient with refractory heart failure requiring advanced intervention (i.e. left ventricular assist device, Status ≤5 heart transplantation) (ACC/AHA Stage D heart failure)
  • Clinically significant, untreated coronary artery disease
  • Recent stroke
  • Other severe valve disorders requiring intervention
  • Need for emergent or urgent surgery for any reason or any planned cardiac surgery within the next 12 months
  • Severe tricuspid regurgitation or tricuspid valve disease requiring surgery
  • Active rheumatic heart disease or rheumatic etiology for MR
  • Known history of untreated, severe carotid stenosis
  • Recent deep vein thrombosis (DVT) or pulmonary embolism (PE)
  • Other medical, social, or psychological conditions that preclude appropriate consent and follow-up, including patients under guardianship
  • Patient in whom a TEE is contraindicated or screening TEE is unsuccessful
  • Mitral valve anatomy which may preclude proper PASCAL or MitraClip access, use and/or deployment or sufficient reduction in mitral regurgitation
  • Severe aortic stenosis or regurgitation
  • Severe COPD

Where in United States

Also in 3 other countries, 18 sites

  • Albany Medical CollegeAlbany, United States
  • University of MichiganAnn Arbor, United States
  • Emory University Hospital and Emory University Hospital MidtownAtlanta, United States
  • Piedmont HealthcareAtlanta, United States
  • Beth Israel Deaconess Medical CenterBoston, United States
  • Brigham and Woman's HospitalBoston, United States
  • Massachusetts General HospitalBoston, United States
  • State University of New York at BuffaloBuffalo, United States
  • St. Vincent Heart CenterCarmel, United States
  • University of VirginiaCharlottesville, United States
  • Northwestern UniversityChicago, United States
  • The Christ HospitalCincinnati, United States
  • Cleveland Clinic FoundationCleveland, United States
  • Henry Ford HospitalDetroit, United States
  • The Cardiac and Vascular Institute Research FoundationGainesville, United States
  • Baylor College of MedicineHouston, United States
  • Houston Methodist HospitalHouston, United States
  • The University of Texas Health Science Center at HoustonHouston, United States
  • University of Iowa Hospitals & ClinicsIowa City, United States
  • St. Luke's Hospital of Kansas CityKansas City, United States
  • CVA Heart Institute KingsportKingsport, United States
  • Scripps Memorial Hospital La JollaLa Jolla, United States
  • Cedars-Sinai Medical CenterLos Angeles, United States
  • Medical Center of the RockiesLoveland, United States
  • Baptist Memorial Hospital-MemphisMemphis, United States
  • Mount SinaiMiami Beach, United States
  • Aurora St. Luke's Medical CenterMilwaukee, United States
  • NYU Langone Hospital - Long IslandMineola, United States
  • Morristown Medical CenterMorristown, United States
  • NCH Rooney Heart InstituteNaples, United States
  • Centennial Medical CenterNashville, United States
  • Saint Thomas Heart at Saint Thomas WestNashville, United States
  • Vanderbilt University Medical CenterNashville, United States
  • Rutgers-RWJMSNew Brunswick, United States
  • Columbia University Medical Center/New York-Presbyterian HospitalNew York, United States
  • Lenox Hill Hospital and North Shore UniversityNew York, United States
  • NYU Langone HealthNew York, United States
  • Sentara Norfolk General HospitalNorfolk, United States
  • Oklahoma CardiovascularOklahoma City, United States
  • UC IrvineOrange, United States
  • AdventHealth OrlandoOrlando, United States
  • Hospital of the University of Pennsylvania/Penn Presbyterian Medical CenterPhiladelphia, United States
  • Banner University Medical CenterPhoenix, United States
  • Allegheny General HospitalPittsburgh, United States
  • The Heart Hospital Baylor PlanoPlano, United States
  • Oregon Health Science UniversityPortland, United States
  • Mayo ClinicRochester, United States
  • Rochester General HospitalRochester, United States
  • Sutter Medical Center SacramentoSacramento, United States
  • Intermountain Medical CenterSalt Lake City, United States
  • Kaiser Permanente-San FranciscoSan Francisco, United States
  • University of California San FranciscoSan Francisco, United States
  • Swedish Medical CenterSeattle, United States
  • Washington University (Barnes-Jewish Hospital)St Louis, United States
  • Stanford UniversityStanford, United States
  • Montefiore Medical CenterThe Bronx, United States
  • Los Robles Hospital and Medical CenterThousand Oaks, United States
  • TMC HealthcareTucson, United States
  • Oklahoma Heart InstituteTulsa, United States
  • MedStar Washington Hospital CenterWashington D.C., United States
  • Pinnacle Health Cardiovascular Institute/ UPMC Pinnacle HarrisburgWormleysburg, United States
  • Lankenau Medical CenterWynnewood, United States
  • Wellspan York HospitalYork, United States

About the trial

What the trial wants to find out

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation (DMR) who have been determined to be at prohibitive risk for mitral valve surgery by the Heart Team, and in patients with functional mitral regurgitation (FMR) on guideline directed medical therapy (GDMT)

The 5 groups in the trial

  • Edwards PASCAL System - CLASP IIDTreatment being tested

    Transcatheter mitral valve repair with the Edwards PASCAL System in patients with degenerative mitral regurgitation

    Treatment: Edwards PASCAL System

  • Abbott Mitraclip System - CLASP IIDExisting treatment, for comparison

    Transcatheter mitral valve repair with the Abbott Mitraclip System in patients with degenerative mitral regurgitation

    Treatment: Abbott Mitraclip System

  • Edwards PASCAL System - CLASP IIFTreatment being tested

    Transcatheter mitral valve repair with the Edwards PASCAL System in patients on guideline directed medical therapy with functional mitral regurgitation

    Treatment: Edwards PASCAL System

  • Abbott Mitraclip System - CLASP IIFExisting treatment, for comparison

    Transcatheter mitral valve repair with the Abbott Mitraclip System in patients on guideline directed medical therapy with functional mitral regurgitation

    Treatment: Abbott Mitraclip System

  • Edwards PASCAL System - Single-Arm RegistryTreatment being tested

    Transcatheter mitral valve repair with the Edwards PASCAL System in patients with mitral regurgitation who were deemed non-randomizable by a central screening committee (CSC) due to complex anatomical features described in the current MitraClip Instructions for Use (IFU) but were considered suitable for the PASCAL system.

    Treatment: Edwards PASCAL System

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Edwards PASCAL TrAnScatheter Valve RePair System Pivotal Clinical Trial (CLASP IID/IIF): A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Mitral Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System Compared to Abbott MitraClip in Patients With Mitral Regurgitation
Publications
Record updated
8 July 2026